MDXH MDxHealth SA IFRS Annual reports only
Services-Medical Laboratories · Nasdaq · SEC CIK 1872529
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY19.8%
TTM net income YoY12.0%
TTM EPS YoY42.2%
Revenue 3-yr CAGR42.8%
Net income 3-yr CAGR—
Margins
Gross margin64.5%
Operating margin-13.4%
Net margin-31.1%
FCF margin-3.1%
EBITDA margin—
Returns
ROE-2,440.4%
ROA-22.0%
ROIC (approx.)-41.8%
Asset turnover0.71x
Leverage & solvency
Liabilities / assets108.2%
Debt / equity—
Current ratio1.08x
Interest coverage-18.33x
Cash quality & payout
Operating cash flow / net income0.07x
Accruals ratio-20.5%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $107.88M | $90.05M |
| Cost of revenue | $38.24M | $34.91M |
| Gross profit | $69.63M | $55.14M |
| R&D expense | $10.35M | $10.55M |
| SG&A expense | $26.93M | $22.80M |
| Operating income | -$14.41M | -$24.72M |
| Interest expense | $786,000 | $384,000 |
| Pretax income | -$35.38M | -$37.69M |
| Income tax | -$1.86M | $382,000 |
| Net income | -$33.52M | -$38.07M |
| EPS (basic) | -0.67 | -1.16 |
| EPS (diluted) | -0.67 | -1.16 |
| Weighted avg. shares (diluted) | 49.96M | 32.86M |
| Balance sheet | ||
| Cash & equivalents | $29.03M | $46.80M |
| Short-term investments | $103,000 | $135,000 |
| Receivables | $14.68M | $14.44M |
| Inventory | $6.74M | $3.87M |
| Current assets | $53.41M | $66.89M |
| PP&E, netmay include right-of-use assets (IFRS) | $4.86M | $4.36M |
| Goodwill | $38.95M | $35.93M |
| Intangibles | $39.42M | $40.59M |
| Total assets | $147.95M | $157.33M |
| Current liabilities | $49.53M | $42.66M |
| Short-term debt | — | $324,000 |
| Long-term debt | $76.20M | $50.97M |
| Total debt | $76.20M | $51.29M |
| Total liabilities | $160.05M | $142.49M |
| Shareholders' equity | -$12.09M | $14.84M |
| Net debt | $47.16M | $4.49M |
| Cash flow statement | ||
| Operating cash flow | -$2.19M | -$18.53M |
| Capital expenditure | $1.16M | $1.19M |
| Free cash flow | -$3.35M | -$19.72M |
| Investing cash flow | -$18.56M | -$1.64M |
| Financing cash flow | $2.96M | $44.60M |
| Stock-based compensation | $2.21M | $1.73M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.